Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Entera Bio has become one of the more striking small-cap biotech setups of the summer — a stock up 65% in a month while short sellers pile in at a pace not seen in years.
The lending market tells the most urgent story right now. Availability has tightened sharply to around 41% — meaning for every share already on loan, only four-tenths of a share remains available to borrow. That is well into "tight" territory, and notably, availability hit its 52-week floor of 33% just last week before bouncing modestly. Cost to borrow has risen to roughly 13.3%, up from under 2% in mid-July — a near-ten-fold increase in five weeks. The speed of that move reflects just how quickly demand for borrows overwhelmed the available lending pool after the stock started rallying.
Short interest itself is the number that grabs attention. It has risen more than ten-fold since late July — from around 47,000 shares shorted on July 23 to over 1.7 million by August 20, now equal to roughly 3.8% of the free float. A 17% weekly rise and a month-on-month increase of over 1,000% are extraordinary figures. That said, the absolute level — 3.8% of float — is not yet extreme in the context of the broader short-selling universe. The story is less about crowded positioning and more about the velocity of the build. Options pricing adds a layer of caution. The put/call ratio runs at 4.1, well above its 20-day average of 3.5, and has stayed elevated all month after spiking from a near-zero reading in late July. The shift from a call-heavy book in mid-July to a heavily put-skewed one now mirrors the short interest surge almost precisely in timing.
The Street is thin on coverage but not entirely silent. HC Wainwright holds the only visible analyst rating — a Buy with a $9 target, trimmed from $10 in late April. At $3.23, that implies roughly 180% upside, though the target is now almost four months old and predates the recent rally. The bull case rests on Entera's oral peptide delivery platform and a pipeline that includes EB613, EB612, and an oral GLP-2 candidate — each targeting markets with limited approved oral alternatives. The bear case is the standard clinical-stage reality: no revenue, ongoing dilution risk, and binary trial outcomes. With an EV of roughly $46 million, the market is still pricing the company closer to its cash than its pipeline potential, which HC Wainwright values at $750 million on a probability-adjusted basis.
Institutional flows add genuine texture. BVF Partners — a specialist healthcare activist — filed a position of nearly 17.1 million shares in early August, a stake built almost entirely this quarter (14.6 million shares added in the most recent period). TCG Crossover and Vivo Capital each reported new positions of over 12 million shares, last reported July 28. Longitude Capital and Seven Fleet Capital also entered as new holders around the same time. The clustering of specialist healthcare funds taking large, fresh positions in late July aligns almost exactly with when short interest began its vertical ascent — suggesting two distinct investor communities arrived simultaneously with opposing convictions about the next catalyst.
Recent earnings reactions give context on how volatile ENTX can be around events. The August 7 report produced a 7.8% one-day move with only a 2.5% gain held by day five. The August 14 event — likely a secondary filing or clinical update — moved 1% on the day but extended to 12.5% over five sessions. The next formal earnings event is not scheduled until November 9, leaving clinical news flow as the primary near-term variable. With borrow costs running high, short interest rebuilding fast, and specialist funds holding large new positions, any material pipeline update between now and November is the moment to watch.
See the live data behind this article on ORTEX.
Open ENTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
